| P50 | author | Pierluigi Viale | Q113862183 |
| | Claudio Viscoli | Q114325513 |
| P2093 | author name string | Giorgio L Colombo | |
| | Sergio Di Matteo | |
| | Antonio Di Biagio | |
| | Vincenzo Colangeli | |
| P2860 | cites work | The cost effectiveness of combination antiretroviral therapy for HIV disease. | Q52067020 |
| | Resource utilization and hospital cost of HIV/AIDS care in Italy in the era of highly active antiretroviral therapy | Q56835329 |
| | Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Versus Fixed-Dose Zidovudine/Lamivudine and Efavirenz in Antiretroviral-Naive Patients | Q58000876 |
| | Providing antiretroviral therapy for HIV infection | Q73614013 |
| | The Lifetime Cost of Current Human Immunodeficiency Virus Care in the United States | Q22242768 |
| | Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies | Q24597052 |
| | Decline in the AIDS and death rates in the EuroSIDA study: an observational study | Q33967061 |
| | A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy | Q35205440 |
| | Changing health environment: the challenge to demonstrate cost-effectiveness of new compounds | Q36117463 |
| | British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). | Q36653838 |
| | The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time | Q36712393 |
| | Antiretroviral therapy and management of HIV infection | Q37770721 |
| | Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients | Q38959219 |
| | Adherence to protease inhibitor therapy and outcomes in patients with HIV infection | Q39605935 |
| | One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects | Q40729054 |
| | Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis | Q42623275 |
| | Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis | Q42635936 |
| | Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study | Q42658845 |
| | Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK. | Q42772430 |
| | Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK. | Q42772436 |
| | Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses | Q43092892 |
| | Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE st | Q43208808 |
| | Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial | Q43300648 |
| | Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks. | Q43472229 |
| | The cost of HIV disease in Northern Italy: the payer's perspective | Q43911880 |
| | Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment | Q44191819 |
| | Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection | Q44509935 |
| | Relative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAART. | Q44744113 |
| | Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial | Q44975155 |
| | Comparison of Markov model and discrete-event simulation techniques for HIV. | Q46103481 |
| | Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study | Q46414306 |
| | Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. | Q46667493 |
| | Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. | Q46900196 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Italy | Q38 |
| P304 | page(s) | 197-205 | |
| P577 | publication date | 2011-10-31 | |
| P1433 | published in | ClinicoEconomics and Outcomes Research | Q5133862 |
| P1476 | title | Cost-effectiveness analysis of initial HIV treatment under Italian guidelines | |
| P478 | volume | 3 | |